Advanced Cell Technology's Dr. Robert Lanza Conference Co-Chair of International Forum on Stem Cells October 16-18, 2008, Tianjin, China.WORCESTER, Mass. -- Advanced Cell Technology, Inc. ("ACT") (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). : ACTC ACTC Apple Certified Technical Coordinator ACTC Almaden Cycle Touring Club ACTC Associated Colleges of the Twin Cities ACTC All Ceylon Tamil Congress (Sri Lanka) ACTC Association Canadienne de Télévision par Câble ) announced today that Dr. Robert Lanza Robert Lanza is is Chief Scientific Officer Advanced Cell Technology (ACT) and Adjunct Professor at the Institute for Regenerative Medicine, Wake Forest University School of Medicine [1]. Lanza received both BA and MD degrees from the University of Pennsylvania. , M.D., the company's Chief Scientific Officer, and Dr. Tao Cheng are Conference Co-Chairs of the International Forum on Stem Cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young , held October 16-18th in Tianjin, China. The conference is organized by the Chinese Academy of Medical Sciences (CAMS) and the National Science Foundation of China. According to the organizers, "The timing, location and booming economy in China offer new exciting opportunities to launch some joint international efforts on stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. research and applications." Dr. Lanza will Chair the opening session of the Conference, which includes Keynote Presentations by Professor Sir Ian Wilmut, Chair of Reproductive Biology and Director of the Scottish Centre for Regenerative Medicine, University of Edinburgh (body, education) University of Edinburgh - A university in the centre of Scotland's capital. The University of Edinburgh has been promoting and setting standards in education for over 400 years. , UK, and Dr. Darwin Prockop, Stearman Chair in Genomic Medicine genomic medicine Molecular medicine The application of molecular methods to clinical medicine; MM encompasses diagnostic methods–eg, Southern, Western, and Northern blot hybridizations, DNA signal amplification by PCR, and use of agents produced by at Texas A&M College of Medicine and Institute for Regenerative Medicine at Scott & White. The conference will include speakers and presenters from stem cell companies and leading academic researchers. Dr. Shi-Jiang Lu, Ph.D., ACT's Director of Stem Cell Differentiation, will discuss the biological properties of hemangioblasts derived from human embryonic stem cells. Other agenda topics include: * Embryonic stem cell derivation and maintenance * Embryonic or germ line germ line n. Cells from which gametes are derived. stem cell differentiation * Reprogramming Reprogramming refers to erasure and remodeling of epigenetic marks, such as DNA methylation, during mammalian development[1]. After fertilization some cells of the newly formed embryo migrate to the germinal ridge and will eventually become the germ cells and "iPS"cells * Somatic somatic /so·mat·ic/ (so-mat´ik) 1. pertaining to or characteristic of the soma or body. 2. pertaining to the body wall in contrast to the viscera. so·mat·ic adj. stem cells * Pathogenic stem cells * Stem cell transplant and tissue engineering * Stem cell manipulations and drug discovery * Stem cell applications and business models * Open discussion on potential international collaborations and advantages of doing stem cell research/business in China For more information, visit: http://www.selectbiosciences.com/conferences/IFSC2008/ Forward-Looking Statements About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. For more information, visit http://www.advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion